Mankind Pharma's EUR 48 Million Bet on a Belgian CAR-T Biotech

A 70% stake, paid in instalments, in a company that has not yet sold a single dose. Here is what the structure says about how Indian pharma plans to buy innovation from now on.

On 15 October 2026, Mankind Pharma's board approved a deal that looks small next to the company's own recent history. It is buying 70% of Armed Cell Therapeutics B.V. (ACTx), a Belgium-incorporated biotech working on next-generation CAR-T cancer therapies, for EUR 48 million, about Rs 511 crore. Compare that with the Rs 13,630 crore Mankind paid in 2024 for full control of Bharat Serums and Vaccines (BSV), and the number looks almost like a rounding error.

It is not one. The ACTx deal is Mankind's first direct move into cell and gene therapy, and the way it has been structured, a 70% stake paid in tranches into a preclinical pipeline, tells you more about where Indian pharma's next decade of dealmaking is headed than the headline number does.

Key takeaways

• Mankind Pharma will invest EUR 48 million through its Netherlands subsidiary for a 70% stake in Armed Cell Therapeutics, a Belgian biotech building next-generation CAR-T cancer therapies.
• The board has approved funding up to EUR 50 million into the subsidiary, so the deal is structured to be paid in instalments, not as a single cheque.
• At roughly Rs 511 crore, this is about 27 times smaller than Mankind's 2024 purchase of Bharat Serums and Vaccines, a deliberately smaller, option-like bet rather than a scale acquisition.
• ACTx's assets trace back to Galapagos (now Lakefront Biotherapeutics) and are led by Paul Stoffels, the former Johnson & Johnson chief scientific officer, alongside John Mellors and Peter Verhaeghe.
• The deal follows a wider pivot across Indian pharma, from buying scale to buying frontier science, that includes Sun Pharma's USD 11.75 billion Organon deal and Sudarshan Pharma's smaller 9.5% stake in a US CAR-T company.
• India already has its own, far cheaper CAR-T therapy in NexCAR19. ACTx's real test is whether its science justifies a price India has already shown it does not need to pay.

What Mankind Actually Bought

Mankind Pharma (NSE: MANKIND) is routing the deal through Mankind Pharma (Netherlands) B.V., a wholly owned subsidiary. The board approved an additional investment of up to EUR 45 million into that subsidiary, on top of an already-approved EUR 5 million, taking the total investment limit to EUR 50 million. The Netherlands entity will then deploy EUR 48 million of that into ACTx, in instalments, for the 70% stake.

ACTx is building what the industry calls armed CAR-T therapies: CAR-T cells engineered with extra payloads meant to make the anti-tumour response deeper and longer lasting, addressing the two problems that limit today's CAR-T drugs, cells that do not persist long enough and tumours that develop resistance. Its lead programmes target non-Hodgkin lymphoma and small cell lung cancer, and it is also pursuing in-vivo CAR-T generation, an approach that would create CAR-T cells inside the patient's body instead of manufacturing them outside it and infusing them back in, a shift that could eventually cut the cost and complexity that keep today's CAR-T therapies out of reach for most patients.

The company itself has an unusual, fast history. It was formed by Paul Stoffels (former chief scientific officer at Johnson & Johnson), John Mellors and Peter Verhaeghe, who in October 2026 bought the preclinical cell therapy pipeline that Galapagos (since renamed Lakefront Biotherapeutics) had abandoned a year earlier after failing to find a strategic buyer. ACTx paid Lakefront EUR 8 million upfront plus up to USD 230 million in milestones. Mankind is now buying 70% of the company holding those same assets, with its own operations spanning Belgium, the Netherlands, and an R&D base in Pittsburgh, Pennsylvania.

Why 70%, Not 100%, and Why It Matters

Compare the structure of this deal with how Mankind bought BSV. BSV was a 100% cash acquisition of a company that already had revenue, in women's health, fertility and critical care. Mankind paid up front for certainty: an established portfolio, a sales force it could plug in immediately, and products already selling.

ACTx has none of that yet. Its lead assets are preclinical. There is no revenue to underwrite, no sales channel to inherit, and years of clinical trials between today and any product reaching a patient. A 100% buyout of a business at that stage would be a bet with no fallback. A 70% stake, funded in instalments against a capped investment ceiling, is closer to a venture-style position: Mankind gets control and first claim on the science, while the tranche structure means it is not obligated to keep funding a programme that stalls in the clinic.

Figure 1. The BSV and ACTx deals sit at opposite ends of Mankind's own playbook: pay fully for certainty, or pay partially for optionality.

This is the real story in the filing. Mankind is not choosing between buying scale and buying innovation. It is using two different deal structures for two different kinds of asset, cash and full control for proven revenue, staged partial-stake capital for unproven science. Expect more Indian pharma majors to follow the same split as they go after frontier biology without betting the balance sheet on any single programme.

Where This Fits in Indian Pharma's Bigger Pivot

This deal did not happen in isolation. Indian pharma's outbound dealmaking has visibly shifted character over the past 18 months, from buying manufacturing scale and branded portfolios to buying a seat at the frontier of drug science.

Deal	Buyer	What changed hands	Size
Organon & Co.	Sun Pharma (Apr 2026)	A full US specialty pharma company; Sun's largest overseas acquisition ever	USD 11.75 billion
Bharat Serums and Vaccines	Mankind Pharma (Jul 2024)	100% of an established women's health and critical care business	Rs 13,630 crore
Armed Cell Therapeutics	Mankind Pharma (Oct 2026)	70% of a preclinical CAR-T biotech, paid in instalments	EUR 48 million (~Rs 511 crore)
MedTherapy Biotechnology	Sudarshan Pharma (Sep 2026)	9.5% of a Boston-based cancer cell and gene therapy company	Undisclosed, minority stake

Two things stand out when the ACTx deal is read against this table rather than on its own. First, ticket size has stopped tracking ambition. Sun Pharma's Organon deal and Mankind's own ACTx deal are both described by their companies as strategic entries into higher-value, innovation-led territory, yet they differ in size by roughly 400 times. Second, the stake size is doing the signalling that deal value used to do. A 100% buyout, like BSV, says we know exactly what we are getting. A 9.5% or 70% stake, like Sudarshan's or Mankind's, says we are paying for the option to find out.

The India Counterpoint Nobody in the Coverage Raised

Every report on this deal describes ACTx's science. None of them ask what it means for India specifically, and that is where the deal gets genuinely interesting for a domestic reader.

India already has an approved, working CAR-T therapy. NexCAR19, developed by IIT Bombay-incubated ImmunoACT and approved by the CDSCO in 2023, treats relapsed B-cell lymphomas and leukaemia at a course price of roughly USD 40,000 to 50,000, against the USD 350,000 to 400,000-plus charged for comparable therapies approved in the US and Europe. It exists precisely because the globally approved price point was never going to clear India's market.

Figure 2. India has already solved the price problem CAR-T faces everywhere else. ACTx's science still has to clear it.

ACTx's own therapies are not priced yet, since they are still preclinical, so this is not a claim that they will cost USD 400,000 in India. It is a question Mankind's own deal team will have had to answer before writing the cheque: does a next-generation CAR-T asset, developed on a US/EU cost base, reach Indian patients at a price the market will bear, or does its destination market stay the US, Europe and private-pay segments of Asia, with India functioning only as Mankind's capital and strategic access, not its launch market? The in-vivo CAR-T approach ACTx is chasing is the piece of the thesis most relevant to India specifically, because it is the one technology path that could eventually make CAR-T manufacturing cheap enough to compete with, rather than sit above, what ImmunoACT has already built domestically.

The Regulatory Path

Three separate compliance layers sit under this one transaction, and each is routine for a deal of this size and shape, worth naming because they shape how a deal like this gets structured and timed.

Layer	What applies	Why it is not a bottleneck here
RBI, outbound investment	Foreign Exchange Management (Overseas Investment) Rules, 2022; automatic route	Automatic route permits an Indian entity to invest abroad up to 400% of net worth without prior RBI approval; Mankind's EUR 50 million ceiling sits well inside that headroom for a company of its size
SEBI, related-party transactions	Regulation 23(5) of the LODR Regulations	Mankind's own filing states the investment into Mankind Netherlands, a wholly owned subsidiary in which the company holds no separate interest, is exempt as a related-party transaction under this provision
Competition Commission of India	Section 5, Competition Act, 2002; de minimis exemption	At this size, the deal falls well under the thresholds that would require CCI notification; Mankind's much larger BSV acquisition did require and receive CCI clearance in 2024, a useful contrast on scale

What to Watch Next

1. Clinical milestones on ACTx's lead programmes in non-Hodgkin lymphoma and small cell lung cancer, since the tranche structure likely ties further funding to exactly these gates.
2. Whether Mankind discloses an India-specific development or pricing plan for any ACTx asset, or keeps the programmes aimed at US and EU-priced markets.
3. Further outbound biotech stakes from Indian pharma majors using the same partial-stake-plus-tranches structure, Sudarshan's MedTherapy stake suggests this is becoming a pattern, not a one-off.
4. Mankind's FY27 commentary on where ACTx sits inside its capital allocation, alongside BSV integration and its existing consumer health and domestic formulations businesses.

One read of this deal is that Mankind just priced what a credible option on frontier cancer science costs for an Indian pharma major right now: about Rs 500 crore, paid in instalments, for a 70% share of a bet that may take a decade to pay off. That is a very different number from what the company paid to buy certainty two years ago, and the gap between the two tells you more about the state of Indian pharma's ambitions than either deal does alone.

This article is general commentary on a publicly announced corporate transaction, not investment advice. Figures are drawn from company filings and media reports as of 19 October 2026 and may change as the deal progresses.